The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Novel targets for T-cell engagers in relapsed/refractory AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, presents evidence for targeted antigen immunotherapy approaches in acute myeloid leukemia (AML), including data from the Phase I study (NCT05143996) of the FLT3xCD3 bispecific T-cell engager CLN-049 in patients with relapsed/refractory (R/R) AML and myelodysplastic syndromes (MDS). Dr Sallman highlights that CLN-049 was well tolerated, with durable responses in heavily pretreated patients, and mentions the upcoming Phase Ib study (NCT07722767) of CLN-049 with azacitidine and venetoclax in the frontline setting. Finally, he discusses other emerging immunotherapeutic approaches, including T-cell engagers targeting cathepsin G, CD70-directed CAR T-cells secreting a T-cell engager, and novel combination strategies. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
